Shopping Cart
Remove All
Your shopping cart is currently empty
ST7612AA1
Copy Product Info
😃Good
Catalog No. T70692Cas No. 1428535-92-5
ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria.
ST7612AA1
Copy Product Info😃Good
Purity: 99.71%
Catalog No. T70692Cas No. 1428535-92-5
ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | In Stock | In Stock | |
| 5 mg | $483 | In Stock | In Stock | |
| 10 mg | $692 | In Stock | In Stock | |
| 25 mg | $1,080 | In Stock | In Stock | |
| 50 mg | $1,490 | In Stock | In Stock | |
| 100 mg | $1,970 | In Stock | In Stock | |
| 500 mg | $3,930 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.71%
ee:97.06%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
ST7612AA1 AI Summary
ST7612AA1 exhibits significant cytotoxicity against human NCI-H460 cells with an IC50 of 66.0 nM and rat L6 cells with an IC50 of 189.0 nM. In addition, it shows antiprotozoan activities against Trypanosoma brucei rhodesiense STIB 900, Trypanosoma cruzi Tulahuen C4, Plasmodium falciparum NF54, and Giardia lamblia G1, with IC50 values of 2510.0 nM, 2100.0 nM, 6570.0 nM, and 8110.0 nM, respectively. The compound also inhibits HDAC-mediated tubulin deacetylation and histone H4 deacetylation in human NCI-H460 cells with IC50 values of 200.0 nM and 5.0 nM, respectively. ST7612AA1 is highly soluble in diluted Solutol HS15 and exhibits high intrinsic clearance in human hepatocytes. Moreover, it shows substantial antitumor activity against various xenografted human cancer cell lines, including HCT116, NCI-H1975, SK-OV-3, MDA-MB-436, and MV4-11, with tumor volume inhibition rates ranging from 35.0% to 89.0% at a dose of 60 mg/kg. Despite its promising antitumor effects, the compound induces toxicity, demonstrated by body weight loss in xenografted mice..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria. |
| Molecular Weight | 405.51 |
| Formula | C20H27N3O4S |
| Cas No. | 1428535-92-5 |
| Smiles | C(N[C@H](C(NC1=CC=CC=C1)=O)CCCCCSC(C)=O)(=O)[C@@H]2NC(=O)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (135.63 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ST7612AA1 | purchase ST7612AA1 | ST7612AA1 cost | order ST7612AA1 | ST7612AA1 chemical structure | ST7612AA1 formula | ST7612AA1 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.